By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AstraZeneca PLC 

15 Stanhope Gate

London  England  W1K 1LN  United Kingdom
Phone: 44-20-7304-5000 Fax: 44-20-7304-5151


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.




CEO: Pascal Soriot

CFO: Marc Dunoyer

CMO: Marc Dunoyer

CTO: Andrew Chen

CCO: Katarina Ageborg

CMO: Sean Bohen


Please click here for clinical trial information.


Please click here for AstraZeneca job opportunities.


AstraZeneca Medications

For more information, visit and follow us on


Key Statistics

Ownership: Public

Web Site: AstraZeneca PLC
Employees: 50,000 worldwide
Symbol: AZN

Company News
AstraZeneca PLC (AZN): Buy The Dip? 8/4/2017 6:03:36 AM
AstraZeneca PLC (AZN) Release: Acalabrutinib Granted Breakthrough Therapy Designation By U.S. FDA For The Treatment Of Patients With Mantle Cell Lymphoma 8/1/2017 7:35:09 AM
AstraZeneca PLC (AZN) Seen as “Tricky” Takeover Target After Big Setback Last Week 8/1/2017 6:48:26 AM
Pharma Giant AstraZeneca PLC (AZN) Scores Another FDA Breakthrough 8/1/2017 6:42:11 AM
AstraZeneca PLC (AZN): Will Pfizer (PFE) Come Knocking Again? 7/31/2017 9:58:39 AM
FDA Calls AstraZeneca PLC (AZN) and MedImmune (AZN)’s Imfinzi a Breakthrough 7/31/2017 6:41:46 AM
AstraZeneca PLC (AZN) Shows The Peril Of Going All-In 7/28/2017 6:12:43 AM
Why AstraZeneca PLC (AZN)'s MYSTIC Trial Failure May be a Bad Sign for Bristol-Myers Squibb (BMY) 7/28/2017 6:05:45 AM
AstraZeneca PLC (AZN) Release: TAGRISSO (Osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer 7/27/2017 6:30:26 AM
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints 7/27/2017 5:51:38 AM